57

2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Embed Size (px)

Citation preview

Page 1: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)
Page 2: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• 2003

• Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Page 3: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• older than 50 years, SBP > 140 mmHg is a much more important cardiovascular disease (CVD) risk factor than DBP

• normal blood pressure at age 55 to 65 years : 80-90 % risk of developing hypertension by the age of 80 to 85 years.

Page 4: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• SBP of 120–139 mmHg or

DBP of 80–89 mmHg : considered as

prehypertensive and require health-promoting lifestyle modification to prevent CVD.

Page 5: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• The relationship between BP and risk of CVD events is continuous, consistent, and independent of other risk factors. The higher the BP, the greater is the chance of heart attack, heart failure, stroke, and kidney disease.

Page 6: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

The risk of developing CVD doubles for every increment of 20 mm Hg SBP or 10 mm Hg of DBP

• The risk of dying of ischemic heart disease and stroke increases progressively and linearly when blood pressure exceeds 115/75 mm Hg.

Page 7: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)
Page 8: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)
Page 9: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Clinical Guidelines

I. Taking Blood Pressure• HT detection begins with proper blood pressure

measurements• Repeated BP measurements will determine whether initial elevations persist and

require prompt attention or have returned to normal and need only periodic surveillance.

• Blood pressure should be measured in a standardized fashion using equipment that meets

certification criteria.

Page 10: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

BP

The following techniques are recommended:

• seated in a chair with backs supported

• arms bared and supported at heart level

• Patients should refrain from smoking or ingesting caffeine during the 30 minutes preceding the measurement.

Page 11: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

BP

• Measurement should begin after at least 5 minutes of rest.

• The appropriate cuff size

• The bladder within the cuff should encircle at least 80 percent of the arm.

• Measurements should be taken preferably with a mercury sphygmomanometer

Page 12: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

BP

• All measurements, including both SBP and DBP, should be recorded.

• The first two or more readings separated by 2 minutes should be averaged when determining risk.

• If the first two readings differ by more than 5 mm Hg, additional readings should be obtained and averaged.

Page 13: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)
Page 14: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)
Page 15: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)
Page 16: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Evaluation of patients with documented

hypertension has three objectives:

1. to assess lifestyle and identify other

cardiovascular risk factors or

concomitantdisorders that may affect

prognosis and guide treatment

2. to reveal identifiable causes of high BP

3. to assess the presence or absence of target organ damage and CVD.

Page 17: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

patient evaluation

• medical history,

• physical examination,

• routine laboratory tests,

• and other diagnostic procedures.

Page 18: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Treatment

Goals of Therapy

• Reduction of cardiovascular and renal morbidity and mortality.

• Treating SBP and DBP to targets that are <140/90 mmHg is associated with a decrease in CVD complications

• hypertension and diabetes or renal disease, the BP goal is <130/80 mmHg.

Page 19: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Lifestyle modifications

(prevention and treatment):

• weight loss,

• reduced sodium intake,

• Dietary Approaches,

• regular aerobic physical activity, and

• limited alcohol intake

Page 20: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Pharmacologic Treatment

• JNC-7 recommends guidelines for the general management of hypertension

uncomplicated hypertension•single or combination therapy with

diuretics, -blockers, or both

Page 21: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Diuretics • Thiazide

• Hydrochlorothiazide

• Loop• Furosemide

• Potassium sparing• Spironolactone

• Combination • Aldactazide

Page 22: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Diuretics

Mode of action

• Reduce plasma volume and extracellular fluid by increasing excretion of sodium

Considerations

• Orthostatic hypotension

• Prolonged use of NSAIDs can reduce antihypertensive effects

Page 23: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Beta-adrenergic blockers• Nonselective

• Propanolol

• Timolol

• Cardioselective

• Metoprolol

• Atenolol

Page 24: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Mode of action• Block beta-adrenergic receptor sites and

probably have direct effects on myocardiumConsiderations• Orthostatic hypotension• Prolonged use of NSAIDs can reduce

antihypertensive effects• May increase serum levels of lidocaine

(reduced hepatic clearance)

Beta-adrenergic blockers

Page 25: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Alpha-adrenergic blockers

• Prazosin

• doxazosin

Page 26: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Alpha-adrenergic blockers

Mode of action

• Block alpha receptor sites on blood vessels producing dilation

Considerations

• Orthostatic hypotension

• Prolonged use of NSAIDs can reduce antihypertensive effects

Page 27: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Alpha-beta blockers

• Labetalol

Page 28: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Alpha-beta blockers

Mode of action

• alpha and nonselective beta-adrenergic receptor blockade

Considerations

• Orthostatic hypotension

• Prolonged use of NSAIDs can reduce antihypertensive effects

Page 29: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Central sympatholytics

• Clonidine

• Guanabenz

• Guanfacine

• Methyldopa

Page 30: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Central sympatholytics

Mode of action• Inhibition of sympathetic outflow from the

central nervous system Considerations• Orthostatic hypotension• Nausea/vomiting• Enhance CNS depressants• Prolonged use of NSAIDs can reduce

antihypertensive effects

Page 31: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Peripheral adrenergic antagonist

Seldom used

• Guanethidine

• Guanadrel

• reserpine

Page 32: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Peripheral adrenergic antagonist

Mode of action

• Deplete tissue stores of catecholamines and serotonin

Considerations

• Orthostatic hypotension

• Enhance CNS depressants

• Prolonged use of NSAIDs can reduce antihypertensive effects

Page 33: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Direct vasodilators

• Hydralazine

• Minoxidil

Page 34: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Direct vasodilators

Mode of action

• Direct dilatation of arteries

Considerations

• Orthostatic hypotension

• Prolonged use of NSAIDs can reduce antihypertensive effects

Page 35: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Angiotensin-converting enzyme inhibitors (ACEI)

• Captopril

• Enalapril

• Ramipril

Page 36: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

ACEI

Mode of action

• Block conversion of angiotensin I to angiotensin II

Considerations

• Neutropenia, thrombocytopenia

• Prolonged use of NSAIDs can reduce antihypertensive effects

Page 37: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Calcium channel blockers

• Diltiazem

• Verapamil

• Nifedipine

• nicardipine

Page 38: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Calcium channel blockers

Mode of action

• Inhibit calcium-ion influx into cardiac and vascular smooth muscle cells

Considerationsgingival hyperplasia

Page 39: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• Thiazide-type diuretics should be used in drug treatment for most patients with uncomplicated hypertension, either alone or combined with drugs from other classes.

• Certain high-risk conditions are compelling

indications for the initial use of other antihypertensive drug classes

(ACEI, beta-blockers, calcium channel blockers).

Page 40: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• If BP > 20/10 mmHg above goal blood pressure, consideration should be given to initiating therapy with two agents, one of which usually should be a thiazide-type diuretic.

Page 41: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• Treatment of complicated hypertension : combinations of medication •ACE inhibitors, •angiotensin II receptor blockers,•α-blockers, α/β-blockers, •calcium antagonists, •and diuretics

Page 42: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• When multiple drugs are used to achieve a target blood pressure of approximately 130/80 mmHg, the possibility of adverse drug interactions increases.

Page 43: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• Local anesthetics are recommended for patients with hypertension because they can decrease pain and increase comfort.

Page 44: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

The selection of a local anesthetic : • duration of the procedure • the need for hemostasis• the required degree of pain

control.

Page 45: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Vasoconstrictors added to local anesthetics to aid in hemostatic control and to increase the duration

• Risk of epinephrine : sympathomimetic effect on cardiac β1-receptors.

Page 46: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• 2% lidocaine with 1:100,000 epinephrine •most commonly used to achieve

the necessary degree of anesthesia for most dental situations.

• maximum recommended dose of local anesthetic solution for HT (poorly controlled) : two 1.8-ml cartridges (total dose of 3.6 ml) with 1:100,000 (0.036 mg) epinephrine per appointment

Page 47: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• lengthy procedures are anticipated, the epinephrine should be diluted to a ratio of 1:200,000

• apprehensive, sweating, or nervous patient likely has increased levels of endogenous epinephrine.

• administration of epinephrine to the nervous or apprehensive stage 2 patient would be contraindicated.

Page 48: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Factor • The type of injection (block versus

infiltration) • vascularity of the area where the local

anesthetic is being deposited • Avoid Norepinephrine or levonordefrin

•unopposed activation of α1-receptors in HT increase the duration of the drug’s effect (activation lead to uncontrolled increases

in BP)

Page 49: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• Contraindications to local anesthetics containing vasoconstrictors include severe uncontrolled hypertension

• cautious when administering local anesthetics at dosages higher than recommended; they should also be aware of the potential interactions between commonly used local anesthetics and antihypertensive drugs

Page 50: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Potential problem related to dental care

1. Stress and anxiety may cause increase in BP; angina, MI or CVA

2. Treated with antihypertensive agents may become nauseated or hypotensive, or may develop orthostatic hypotension

3. Excessive use of vasopressors may cause significant elevation of blood pressure

4. Sedative medication may bring about hypotensive episode

Page 51: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Tx. with antihypertensive agents a. Reduce stress and anxiety by premedication,

short appointments, nitrous oxide ( avoid

hypoxia )

b. if overly stressed, terminate appointment

c. avoid orthostatic hypotension (changing

position slowly, supporting)

d. avoid stimulating gag reflex

e. select sedative medication and dosage

cautiously

Page 52: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Drug considerations

a. use LA with minimal concentration (epinephrine

0.036 mg); aspirate before injection and injection

slowly

b. caution when using vasoconstrictors in patient

taking a nonselective beta-blocker

c. do not use gingival packing material that contains

epinephrine

d. reduce dosage of barbiturates and other sedative

(action may enhance by antihypertensive agent)

e. epinephrine used judiciously with MAO inhibitor

Page 53: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• Determining Risk / Providing Dental Treatment

Page 54: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Normal/Prehypertension

• Systolic 139 or lower or

• Diastolic 89 or lower

No contraindications to elective dental treatment.

Page 55: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Stage 1 HTN

• Systolic 140 - 159 or

• Diastolic 90 - 99

1. Retake and confirm blood pressure.

2. Proceed with elective dental treatment.

3. Monitor BP during appointment.

Page 56: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

Stage 2 HTN• Systolic 160 or higher or • Diastolic 100 or higher 1. Retake and confirm blood pressure. 2. Emergency or non- invasive elective treatment only 3. Monitor BP during appointment. 4. Refer patient to physician for medical evaluation. 5. Medical consult required prior to elective dental treatment.

Page 57: 2003 Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)

• Systolic >210 or Diastolic >120

1. Retake and confirm blood pressure with

alternate device

2. If blood pressure is unchanged, consider

immediate referral of the patient to a

physician or emergency room for evaluation.

3. No treatment of any type

4. Medical consult required prior to any

dental treatment.